Loading company details...
Latest Form 4 (Jul 29, 2026): AH Bio Fund II, L.P. (10% Owner): Conversion of 2,051,742 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 29, 2026 | AH Bio Fund II, L.P. | Conversion | 2,051,742 | n/a |
| Jul 29, 2026 | Carl L. Gordon | Conversion | 348,825 | n/a |
| Jul 29, 2026 | ORBIMED ADVISORS LLC | Conversion | 348,825 | n/a |
| Jul 29, 2026 | Jennifer A. Doudna | Conversion | 12,511 | n/a |
| Jul 29, 2026 | Behzad Aghazadeh | Purchase | 2,333,333 | $35.00M |
| Jul 28, 2026 | Brett Staahl | Grant/Award | 4,755 | n/a |
| Jul 28, 2026 | Svetlana Lucas, Chief Business Officer | Purchase | 3,000 | $45.0K |
| Jul 28, 2026 | Benjamin L. Oakes, President, CEO | Grant/Award | 12,969 | n/a |
| Jul 28, 2026 | Carl L. Gordon | Grant/Award | 14,725 | n/a |
| Jul 28, 2026 | James Dean Watson | Grant/Award | 14,725 | n/a |